Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14N8O5S4 |
| Molecular Weight | 514.582 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O
InChI
InChIKey=UEQVTKSAEXANEZ-YCRCPZNHSA-N
InChI=1S/C15H14N8O5S4/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22)/b21-8-/t9-,13-/m1/s1
| Molecular Formula | C15H14N8O5S4 |
| Molecular Weight | 514.582 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11400319Curator's Comment: description was created based on several sources, including
http://google.com/patents/EP0467647B1 | https://www.ncbi.nlm.nih.gov/pubmed/11400306 | https://www.ncbi.nlm.nih.gov/pubmed/8585742 | https://www.ncbi.nlm.nih.gov/pubmed/9612604
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11400319
Curator's Comment: description was created based on several sources, including
http://google.com/patents/EP0467647B1 | https://www.ncbi.nlm.nih.gov/pubmed/11400306 | https://www.ncbi.nlm.nih.gov/pubmed/8585742 | https://www.ncbi.nlm.nih.gov/pubmed/9612604
Cefmatilen (codenamed S-1090) is an orally-active cephalosporin antibiotic, that shows high activity against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.79 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.78 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.01 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.58 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.1 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4.25 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6.1 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.98 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20.35 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
25.51 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
11.37 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
15.06 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
19.25 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
27.52 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
39.53 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24.89 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.23 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.77 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.89 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.99 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.84 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.08 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.08 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.53 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/ |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CEFMATILEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29681381/ |
CEFMATILEN plasma | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: |
Other AEs: ALT increased... |
400 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| ALT increased | 33% | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8585742
The bactericidal activities of S-1090 and the other agents at four times the MIC for Escherichia coli ATCC 25922 were determined. An overnight culture in Mueller-Hinton broth was inoculated into fresh broth, and the mixture was incubated, with constant shaking, until the viability reached 2 3 10^6 to 3 3 10^6 CFU/ml. After the addition of antibiotics, the cultures were incubated at 358C and the number of viable cells was determined.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:11 GMT 2025
by
admin
on
Mon Mar 31 18:29:11 GMT 2025
|
| Record UNII |
T750UM24H8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50161236
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
300000037037
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
T750UM24H8
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
140128-74-1
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
C419864
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
CEFMATILEN
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
6400678
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104438
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
C76168
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY | |||
|
7839
Created by
admin on Mon Mar 31 18:29:12 GMT 2025 , Edited by admin on Mon Mar 31 18:29:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|